Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals, Inc. (AMEX:ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B in patients aged 55 and older with active relapsed or refractory acute myeloid leukemia (r/r AML). The primary endpoint of durable Complete Remission (dCR) at 6-months was met with high statistical significance (p<0.0001), showing 22% of patients achieved dCR compared to 0% in the control arm. Secondary endpoints also demonstrated significant improvements in Event-Free Survival (EFS) and overall survival. Notably, Iomab-B showed a favorable safety profile with lower rates of sepsis and other adverse events. A Biologics License Application is planned for 2023.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced it will present the results of its pivotal Phase 3 SIERRA trial for Iomab-B at the Transplantation & Cellular Therapy Meetings, set for 5:00 PM EST on February 18, 2023. The investor call at 6:00 PM EST will reveal topline results, showcasing Iomab-B's role as a targeted radiotherapy aimed at increasing access to bone marrow transplants for older patients with active, relapsed, or refractory acute myeloid leukemia. The trial met its primary endpoint with statistical significance, and Actinium plans to submit a Biologics License Application to the FDA following these results.

Actinium Pharmaceuticals (ATNM) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance Actimab-A for treating acute myeloid leukemia (AML). The NCI will sponsor clinical trials while Actinium provides Actimab-A to clinical sites. The collaboration allows Actimab-A to be available at over 2,000 sites within leading oncology networks, aiming for its study both alone and in combination with existing therapies. Executive comments highlight the potential of Actimab-A, particularly for relapsed or refractory AML patients, and the initiative's alignment with Actinium's strategic goals.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced its management will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 19, 2023, at 10:30 AM EST. The event will showcase over 30 small and mid-cap healthcare companies focusing on innovative cancer therapies. Actinium is known for its advanced radiotherapy products, including I-131 apamistamab (Iomab-B), which has shown positive results in clinical trials for treating acute myeloid leukemia. The presentation will be available for replay on Actinium's website and the conference site.

Actinium Pharmaceuticals (ATNM) announced that the full data from its pivotal Phase 3 SIERRA trial of Iomab-B will be presented at the TCT Tandem Meetings on February 18, 2023. The SIERRA trial met its primary endpoint with a statistically significant p-value of <0.0001, indicating durable Complete Remission in older patients with acute myeloid leukemia. Following the presentation, the company plans a conference call at 6:00 PM EST on the same day. Iomab-B aims to improve access to bone marrow transplants, having shown increased survival rates in prior studies.

Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced a collaboration with Columbia University to study Actimab-A, a targeted radiotherapy for acute myeloid leukemia (AML). The partnership focuses on the use of gene-edited hematopoietic stem cells (eHSCs) to eliminate residual leukemia cells post-transplant. Preliminary results show promising data: 53% one-year and 32% two-year overall survival rates, with a 67% overall response rate and 72% measurable residual disease negativity in patients. The findings will be presented at the American Society of Hematology Annual Meeting on December 10, 2022.

Actinium Pharmaceuticals (ATNM) showcased promising results from its Phase 1 trial of Actimab-A combined with CLAG-M in treating relapsed or refractory acute myeloid leukemia (AML). Highlights include a median overall survival of 12 months, with 1-year and 2-year survival rates at 53% and 32%, respectively—significantly higher than existing treatments. The trial involved patients with adverse cytogenetics, including TP53 mutations. Data will be presented at the ASH Annual Meeting on December 10, 2022, enhancing the potential for Actimab-A's use as a backbone therapy in AML.

Actinium Pharmaceuticals has appointed Caroline Yarbrough as Chief Commercial Officer to lead the commercialization of Iomab-B. Previously with Novartis, Caroline has extensive experience in oncology and managing billion-dollar portfolios. CEO Sandesh Seth emphasized her expertise in launching cancer therapies and her role in expanding access to bone marrow transplants for elderly patients with acute myeloid leukemia. The company aims to file a Biologics License Application for Iomab-B, which recently showed significant efficacy in a pivotal Phase 3 trial.